Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
AOL15d
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
The trial evaluated monotherapy ivonescimab against monotherapy Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer ...
clinicaltrialsarena16d
Summit’s checkpoint inhibitor trumps Keytruda in lung cancer trial
Summit Therapeutics’s drug ivonescimab reduced the risk of lung cancer progression or death by nearly half, compared to MSD’s blockbuster drug Keytruda (pembrolizumab) in Phase III data showcased on 8 ...
Johns Hopkins Medicine16d
Poison Ivy Rash in Children
What is poison ivy rash? Poison ivy rash is an allergic reaction to poison ivy. Poison ivy is very common plant in the U.S. It is similar to two other plants called poison oak and poison sumac. The ...
Nasdaq18d
Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More
Merck’s Keytruda Combo for Urothelial Carcinoma Gets EU Approval: The European Commission granted approval to Merck’s Keytruda in combination with Astellas/Pfizer’s antibody-drug conjugate ...
MarketWatch21d
Merck Gets EU Approval for Keytruda Cancer Therapy
Merck's Keytruda therapy received approval from the European Union, in combination with antibody-drug Padcev, as a first-line cancer treatment. The pharmaceutical company said Tuesday that the ...
Business Insider25d
IO Biotech's Phase 3 Trial Data Fails To Show Superiority In ORR For IO102-IO103 With KEYTRUDA
(RTTNews) - IO Biotech (IOBT) announced that the Independent Data Monitoring Committee found the data from the Pivotal Phase 3 Trial of IO102-IO103 in combination with KEYTRUDA (pembrolizumab ...
healthshots25d
How to choose the right body lotion: A complete buying guide for your skin
Are you confused about which body lotion to pick for your skin type? This guide will help make a wise decision. This buying guide will help you choose the best body lotion. Image courtesy: Adobe Stock ...
Nasdaq25d
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
Merck MRK decided to discontinue two separate phase III studies, KEYNOTE-867 and KEYNOTE-630, evaluating its blockbuster drug Keytruda in patients with certain types of lung cancer and skin cancer ...
health.economictimes.indiatimes26d
Merck scraps two late-stage trials of cancer drug Keytruda
London: Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...